In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors